NEU chart, page-1895

If you're looking at the financial performance of Neuren in the near term then this year will be less than last and next year is possibly a lot worse if you assume they won't make the $500 million annual sales milestone. So from that POV a drop in share price can be justified but it completely discounts the success with 2591 and the fact that there will be continued growth in Daybue sales as more very young patients are diagnosed and Canada and Europe come online. I'm playing the long game and view this as a buying opportunity because the Phase 2 results should be replicable in a larger study and any successful Phase 3 mean 2591 can't be ignored any more and will add billions to Neuren's estimated value.